Company: IMRX
Filing Date: 2025-04-21
Form Type: DEF 14A
Source: 0001790340-25-000053
Chunk: 44

Company: Immuneering Corp
Filing Date: 2025-04-21
Form: DEF 14A
Chunk 44
---
 an additional annual fee as follows:

• Chair of the Board of Directors or lead independent director, $30,000 (the “COB or LID Retainer”);

• chair of the audit committee, $15,000;

• audit committee member other than the chair, $7,500;

• chair of the compensation committee, $10,000;

• compensation committee member other than the chair, $5,000;

• chair of the nominating and corporate governance committee, $8,000; and

• nominating and corporate governance committee member other than the chair, $4,000.

Beginning with annual retainer fees earned in 2024, each non-employee director may elect to receive an option to purchase shares of our Class A common stock (an “Elective Option”) in lieu of the entire amount of his or her Base Retainer and, if applicable, his or her COB or LID Retainer, in each case that will be earned in a given calendar year. For calendar year 2024, each of Peter Feinberg and Laurie B. Keating elected to receive an Elective Option in lieu of a cash Base Retainer. Each non-employee director that elects to receive an Elective Option by no later than November 30 of the calendar year preceding the calendar year to which the election relates will receive an Elective Option on January 1 of the calendar year to which the election relates covering a number of shares determined in accordance with the non-employee director compensation program. If we increase the Base Retainer and/or the COB or LID Retainer during the calendar year to which an Elective Option relates, then the non-employee director will receive the applicable excess in cash.

<div align='center'>29</div>

TABLE OF CONTENTS

Stock options granted to our non-employee directors under the 2021 Plan pursuant to the non-employee director compensation program have an exercise price equal to the fair market value of our common stock on the date of grant, as determined under the 2021 Plan, and will expire not later than ten years after the date of grant. The stock options granted upon a director’s initial election or appointment vest in 36 substantially equal monthly installments following the date of grant. Elective Options vest as to 25% of the underlying shares on each quarterly anniversary of the date of grant. The stock options granted annually to directors vest in 12 substantially equal monthly installments following the date of grant. In addition, all unvested